期刊文献+

Changes in the frequency of myeloid-derived suppressor cells after transarterial chemoembolization with gelatin sponge microparticles for hepatocellular carcinoma 被引量:2

Changes in the frequency of myeloid-derived suppressor cells after transarterial chemoembolization with gelatin sponge microparticles for hepatocellular carcinoma
下载PDF
导出
摘要 Purpose: A series of clinical studies have established the safety and efficacy of transcatheter arterial chemoembolization(TACE) with gelatin sponge microparticles(GSMs) in treating hepatocellular carcinoma(HCC). HCC can lead to obvious necrosis inside tumors, especially larger ones, although it is unclear whether such necrotic tumor tissue can induce favorable immune reactions against the tumor. Myeloid-derived suppressor cells(MDSCs)have immunosuppressive functions and are currently considered a very important cell type affecting tumor immunity. This study observed changes in MDSC frequency in peripheral blood before and after GSM–TACE to evaluate the effect on the immune function of HCC patients.Methods: Eight patients diagnosed with HCC underwent GSM–TACE treatment in the Hepatobiliary Interventional Department of Beijing Tsinghua Chang Gung Hospital, Beijing, China;we followed up with the patients over a period of 30 days post-surgery. We used flow cytometry(FCM) to quantify the frequency of MDSCs in peripheral blood before TACE, 10 days after surgery and 30 days after surgery.Results: MDSC frequency after GSM–TACE had a significant downward trend. Pre-TACE, it was 30.73% ? 11.93%,decreasing to 18.60% ? 11.37% at 10 days after operation. This decrease was not statistically significant(P > 0.05). MDSC frequency was even lower 30 days after TACE(7.63% ? 7.32%) than at 10 days after TACE(P < 0.05), and there was a significant difference compared with pre-TACE(P < 0.001). We evaluated tumor response at 30 days after GSM–TACE according to the Modified Response Evaluation Criteria in Solid Tumors(mRECIST), and all eight patients showed partial response(PR).Conclusion: Our results confirmed that GSM–TACE was beneficial for improving anti-tumor immunity in the treatment of HCC. Purpose: A series of clinical studies have established the safety and efficacy of transcatheter arterial chemoembolization(TACE) with gelatin sponge microparticles(GSMs) in treating hepatocellular carcinoma(HCC). HCC can lead to obvious necrosis inside tumors, especially larger ones, although it is unclear whether such necrotic tumor tissue can induce favorable immune reactions against the tumor. Myeloid-derived suppressor cells(MDSCs)have immunosuppressive functions and are currently considered a very important cell type affecting tumor immunity. This study observed changes in MDSC frequency in peripheral blood before and after GSM–TACE to evaluate the effect on the immune function of HCC patients.Methods: Eight patients diagnosed with HCC underwent GSM–TACE treatment in the Hepatobiliary Interventional Department of Beijing Tsinghua Chang Gung Hospital, Beijing, China; we followed up with the patients over a period of 30 days post-surgery. We used flow cytometry(FCM) to quantify the frequency of MDSCs in peripheral blood before TACE, 10 days after surgery and 30 days after surgery.Results: MDSC frequency after GSM–TACE had a significant downward trend. Pre-TACE, it was 30.73% ? 11.93%,decreasing to 18.60% ? 11.37% at 10 days after operation. This decrease was not statistically significant(P > 0.05). MDSC frequency was even lower 30 days after TACE(7.63% ? 7.32%) than at 10 days after TACE(P < 0.05), and there was a significant difference compared with pre-TACE(P < 0.001). We evaluated tumor response at 30 days after GSM–TACE according to the Modified Response Evaluation Criteria in Solid Tumors(mRECIST), and all eight patients showed partial response(PR).Conclusion: Our results confirmed that GSM–TACE was beneficial for improving anti-tumor immunity in the treatment of HCC.
出处 《Journal of Interventional Medicine》 2019年第1期21-26,共6页 介入医学杂志(英文)
基金 Supported by a grant from National Natural Science Foundation of China(grant number 81571783) National Major Project for Infectious Diseases of China(2017ZX100203205005)
关键词 Gelatin sponge microparticles–transcatheter arterial chemoembolization(GSMs-TACE) Hepatocellular carcinoma Myeloid-derived SUPPRESSOR cells(MDSCs) Immunology Gelatin sponge microparticles–transcatheter arterial chemoembolization(GSMs-TACE) Hepatocellular carcinoma Myeloid-derived suppressor cells(MDSCs) Immunology
  • 相关文献

参考文献4

二级参考文献33

  • 1Yu Ma,Yi Wan,Li-Geng Duan,Xiao-Li Chen,The Research Unit of Hepato-Bilio-Pancreatology and Department of Hepatic Surgery,West China Hospital of Sichuan University,Chengdu 610041,Sichuan Province,China Dong-Hui Luo,Chuan-Qin Xia,College of Chemistry,Sichuan University,Chengdu 610041,Sichuan Province,China Lin Li,Department of Nuclear Medicine and The National Key Discipline of Medical Imaging and Nuclear Medicine,West China Hospital of Sichuan University,Chengdu 610041,Sichuan Province,China.Direct in vivo injection of ^(131)I-GMS and its distribution and excretion in rabbit[J].World Journal of Gastroenterology,2010,16(17):2120-2128. 被引量:3
  • 2张浩,郑树森,蒋国平,周琳,谢海洋.小鼠肝癌树突状细胞融合瘤苗抗肿瘤作用的研究[J].中华肝脏病杂志,2004,12(11):648-651. 被引量:11
  • 3罗剑钧,王建华,刘清欣,陈颐,颜志平.微球联合碘油栓塞治疗肝癌的初步经验[J].介入放射学杂志,2007,16(3):162-164. 被引量:12
  • 4Mazzaferro V,Regalia E,Doci R,et al.Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. New England Journal of Medicine, The . 1996
  • 5Livraghi T,Goldberg SN,Lazzaroni S,et al.Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions. Radiology . 2000
  • 6The Cancer of the Liver Italian Program Investigators.A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology . 1998
  • 7Kim Kang Mo,Kim Jong Hoon,Park Ik Soo,Ko Gi-Young,Yoon Hyun-Ki,Sung Kyu-Bo,Lim Young-Suk,Lee Han Chu,Chung Young Hwa,Lee Yung Sang,Suh Dong Jin.Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion. Journal of Gastroenterology . 2009
  • 8Johannes Lammer,Katarina Malagari,Thomas Vogl,Frank Pilleul,Alban Denys,Anthony Watkinson,Michael Pitton,Geraldine Sergent,Thomas Pfammatter,Sylvain Terraz,Yves Benhamou,Yves Avajon,Thomas Gruenberger,Maria Pomoni,Herbert Langenberger,Marcus Schuchmann,Jerome Dumortier,Christian Mueller,Patrick Chevallier,Riccardo Lencioni.Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study[J]. CardioVascular and Interventional Radiology . 2010 (1)
  • 9Lencioni Riccardo,Chen Xiao-Ping,Dagher Lucy,Venook Alan P.Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved?. The Oncologist . 2010
  • 10Leung Thomas W T,Tang Amanda M Y,Zee Benny,Lau W Y,Lai Paul B S,Leung K L,Lau Joseph T F,Yu Simon C H,Johnson Philip J.Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer . 2002

共引文献78

同被引文献13

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部